Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | STAT6 | P42226 | 5/20 | 0.53 |
| ▸ | CASR | P41180 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ASPH | Q12797 | 3/20 | 0.51 |
| ▸ | KDM8 | Q8N371 | 3/20 | 0.51 |
| ▸ | RIOX2 | Q8IUF8 | 2/20 | 0.51 |
| ▸ | KDM6B | O15054 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.44 |
| ▸ | MERTK | Q12866 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3442955 | 0.88 | ATM (0.57) | HDAC3HDAC1HDAC2HDAC6STAT6 | |
| SCHEMBL3443768 | 0.85 | ALDH1A1 (0.62) | STAT6CASRKDM4EATMTHRB | |
| SCHEMBL3443139 | 0.84 | STAT6 (0.50) | HDAC3HDAC1HDAC2HDAC6STAT6 | |
| SCHEMBL3442807 | 0.84 | HDAC3 (0.51) | HDAC3HDAC1HDAC2HDAC6STAT6 | |
| SCHEMBL3443622 | 0.84 | STAT6 (0.48) | HDAC3HDAC1HDAC2HDAC6STAT6 | |
| SCHEMBL3443114 | 0.84 | HDAC3 (0.51) | HDAC3HDAC1HDAC2HDAC6STAT6 | |
| SCHEMBL11084759 | 0.84 | STAT6 (0.58) | HDAC3HDAC1HDAC2HDAC6STAT6 | |
| SCHEMBL32671629 | 0.83 | RAB9A (0.58) | HDAC3HDAC1HDAC2HDAC6STAT6 | |
| SCHEMBL6016301 | 0.82 | MEN1 (0.46) | KDM4EATMADORA1 | |
| SCHEMBL3443209 | 0.81 | CASR (0.55) | HDAC3HDAC1HDAC2HDAC6STAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812031-B2 | such as 2-Dimethylamino-4-phenylpyrimidine-5-carboxylic acid [2-hydroxy-2-(3-hydroxyphenyl)ethyl]methyl amide, used for the treatment of obesity, including obesity of the non-insulin-dependent diabetes patients, sleeping disorders, stroke, nausea and vomiting | SANOFI-AVENTIS (FR) | 2010-10-12 | — | — | US | claimed |
| EP-1718632-B1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SANOFI AVENTIS (FR) | 2009-04-22 | — | — | EP | claimed |
| JP-2007522197-A | — | — | 2007-08-09 | — | — | JP | claimed |
| US-20070043037-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2007-02-22 | — | — | US | claimed |
| EP-1718632-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2006-11-08 | — | — | EP | claimed |
| WO-2005075458-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTORS ANTAGONISTS | SANOFI-AVENTIS (FR) | 2005-08-18 | — | — | WO | claimed |
| US-7812031-B2 | such as 2-Dimethylamino-4-phenylpyrimidine-5-carboxylic acid [2-hydroxy-2-(3-hydroxyphenyl)ethyl]methyl amide, used for the treatment of obesity, including obesity of the non-insulin-dependent diabetes patients, sleeping disorders, stroke, nausea and vomiting | SANOFI-AVENTIS (FR) | 2010-10-12 | — | — | US | disclosed |
| EP-1718632-B1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SANOFI AVENTIS (FR) | 2009-04-22 | — | — | EP | disclosed |
| US-20070043037-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2007-02-22 | — | — | US | disclosed |
| EP-1718632-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005075458-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTORS ANTAGONISTS | SANOFI-AVENTIS (FR) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043037-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | HDAC3 2223/4885HDAC1 2245/4885HDAC2 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.